Study Details

OVERVIEW

Multi-center, Canadian, Non-interventional, Cohort Study of the Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adult Patients Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF) (BIC-STaR)

PROTOCOL SUMMARY

The primary objective of this study is to evaluate HIV-1 RNA suppression, defined as HIV-1 RNA <50 copies/mL, at 12 months after initiating or switching to Bictegravir/ Emtricitabine/Tenofovir alafenamide (B/F/TAF).

Participation Requirements

Age

18 Years +

Sex

All

Healthy Volunteers

Medical Condition

HIV-1-infection

Gender

N/A

Date

November 2018 - May 2024

Study Type

Observational

Study Phase

Product

B/F/TAF

Eligibility Information

Inclusion Criteria

HIV-1 infection
Signed informed consent
Initiating treatment with B/F/TAF in accordance with the product monograph

Exclusion Criteria

Participation in any other observational or interventional clinical trial without prior approval from the Medical Monitor

Locations

Locations (6)

Clinique Medicale du Quartier Latin

Montréal, Canada, H2L 4E9

University of Ottawa

Ottawa, Canada, K1N 6N5

Regina General Hospital

Regina, Canada, S4P 0W5

St. Clair Medical Association/Balmoral Clinic

Toronto, Canada, M4T3A7

Maple Leaf Research

Toronto, Canada, M5G 1K2

Spectrum Health

Vancouver, Canada, V6Z 2T1

Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (BIC-STaR)